Comparative Efficacy of Sparsentan and Irbesartan in Focal Segmental Glomerulosclerosis Management
|
Reviewed & Translated by Dat Tien Nguyen, B.A, ScM.
|
Posted on February 21st, 2024
|
Water retention regulated by the renin-angiotensin-aldosterone system (RAAS) heightens the susceptibility to focal segmental glomerulosclerosis. The administration of an agent capable of inhibiting the RAAS system has demonstrated efficacy in mitigating the proteinuria linked to renal impairment. Consequently, a study was undertaken to assess the comparative effectiveness of Sparsentan, an endothelin-angiotensin receptor antagonist, and Irbesartan, an angiotensin II receptor blocker, in the management of focal segmental glomerulosclerosis.
The phase 3 clinical trial involved 371 patients diagnosed with focal segmental glomerulosclerosis, characterized by a urinary protein-to-creatinine ratio exceeding 1.5 and an estimated glomerular filtration rate (eGFR) of at least 30 ml per minute per 1.73 square meters of body surface area. Random assignment allocated patients to receive oral treatment once daily with either 800 mg of Sparsentan or 300 mg of Irbesartan. After 36 weeks, researchers observed that proteinuria resolution occurred in 42% of the Sparsentan group, compared to only 20% in the Irbesartan group. This benefit persisted through the 108th week of the study; however, there was no significant disparity in eGFR between the two groups. The study suggested that the heterogeneity of the study cohort and the concurrent usage of immunosuppressant can explain the lack of differences in eGFR.
The phase 3 clinical trial involved 371 patients diagnosed with focal segmental glomerulosclerosis, characterized by a urinary protein-to-creatinine ratio exceeding 1.5 and an estimated glomerular filtration rate (eGFR) of at least 30 ml per minute per 1.73 square meters of body surface area. Random assignment allocated patients to receive oral treatment once daily with either 800 mg of Sparsentan or 300 mg of Irbesartan. After 36 weeks, researchers observed that proteinuria resolution occurred in 42% of the Sparsentan group, compared to only 20% in the Irbesartan group. This benefit persisted through the 108th week of the study; however, there was no significant disparity in eGFR between the two groups. The study suggested that the heterogeneity of the study cohort and the concurrent usage of immunosuppressant can explain the lack of differences in eGFR.